FDA
Categories
Conferences
- AACR
- ASCO
- SABCS
- ASH
- MOASC
About
Contact
Advertise

Advertisement

X (Twitter) LinkedIn Facebook

X (Twitter) LinkedIn Facebook YouTube

FDA
Categories
Conferences
- AACR
- ASCO
- SABCS
- ASH
- MOASC
About
Contact
Advertise

Home » ALPN-101 #ASH19 @AlpineImmuneSci

Immunotherapy

ALPN-101 #ASH19 @AlpineImmuneSci

By EditorDecember 18, 2019No Comments1 Min Read

Twitter LinkedIn Facebook Email

Share

Twitter LinkedIn Facebook Email

Jan Hillson, MD of @AlpineImmuneSci disucsses ALPN-101.

Follow on X (Twitter) Follow on LinkedIn Follow on Facebook Follow on Google News

Share. Twitter LinkedIn Facebook Email

Related Posts

Immunotherapy Side Effects Under Scrutiny: New Data on Bone Density and T-Cell Insights

AACR 3 Mins Read

Immunotherapy Revolution Unveiled: How TLS-Derived Antibodies Are Changing Cancer Treatment AACR Io 2025

AACR 4 Mins Read

AACR IO 2025: Revolutionary Insights into Desmoplastic Melanoma Treatment – Kari L Kendra, MD, PHD

AACR 5 Mins Read

Recent Posts

AACR – Douglas Hanahan, PhD, FAACR, Receives 2025 Pezcoller-AACR Award for Cancer Research Excellence
Immunotherapy Side Effects Under Scrutiny: New Data on Bone Density and T-Cell Insights
FDA Approves TEVIMBRA for First-line Treatment of Advanced Esophageal Squamous Cell Carcinoma
Renal Cell Carcinoma TiNivo-2 Study: Patient-Reported Outcomes in Treatment Post-ICI
FDA Grants Priority Review Zongertinib for HER2-Mutant NSCLC | Breakthrough in Lung Cancer Treatment

Connect With Us on Social

Facebook
Twitter
LinkedIn
YouTube

Donate

Advertise On OncologyTube.com

X (Twitter) LinkedIn Facebook

FDA
Categories
Conferences
- AACR
- ASCO
- SABCS
- ASH
- MOASC
About
Contact
Advertise

© 2025 Copyright Protected Medicus Networks, Inc..

Type above and press Enter to search. Press Esc to cancel.

×